Watch ALT. Know when insiders buy.
One email the day a filing lands. Free.
ALT
Altimmune, Inc.
3.42
+0.19 +5.88%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $665.3MP/E —DIV YIELD —FCF YIELD -11.51%REV TTM —NET INCOME −$91.8MNET CASH $28.3M52W 2.59 – 6.18SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$26.2M | −$22.8M | — | -0.12 | −$24.2M | $32K | −$24.3M | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$24.2M | −$22.6M | — | -0.18 | −$20.9M | $21K | −$21M | Aug 12 |
| Q4 2025 · Dec 31derived | $26K | +420.0% | — | −$28.9M | −$27.4M | — | -0.26 | −$19.4M | $1K | −$19.4M | Mar 6 |
| Q3 2025 · Sep 30 | $5K | +0.0% | — | −$20.9M | −$19M | — | -0.21 | −$11.9M | $0 | −$11.9M | Nov 6 |
| Q2 2025 · Jun 30 | $5K | +0.0% | — | −$22.9M | −$22.1M | — | -0.27 | −$19.4M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | $5K | +0.0% | — | −$21.8M | −$19.6M | — | -0.26 | −$16.8M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | $5K | −86.5% | — | −$24.9M | −$23.2M | — | -0.33 | −$18.3M | — | — | Mar 6 |
| Q3 2024 · Sep 30 | $5K | −98.6% | — | −$24.8M | −$22.8M | — | -0.32 | −$27.1M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | $5K | — | — | −$26.7M | −$24.6M | — | -0.35 | −$18.1M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | $5K | — | — | −$26.8M | −$24.4M | — | -0.34 | −$16.4M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | $37K | — | — | −$33.6M | −$31.6M | — | -0.56 | −$16.5M | $0 | −$16.5M | Feb 27 |
| Q3 2023 · Sep 30 | $362K | — | — | −$22.5M | −$20.7M | — | -0.39 | −$20.5M | $0 | −$20.5M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $41K | — | −$94.5M | −$88.1M | -214861.0% | -1.00 | −$67.5M | $11K | −$67.5M | — | — |
| FY2024 · to Dec 31 | $20K | — | −$103.2M | −$95.1M | -475295.0% | -1.34 | −$79.8M | — | — | — | — |
| FY2023 · to Dec 31 | $426K | — | −$95.9M | −$88.4M | -20762.2% | -1.66 | −$75.8M | $47K | −$75.9M | — | — |
| FY2022 · to Dec 31 | −$68K | — | −$87.7M | −$84.7M | 124577.9% | -1.81 | −$62.6M | $126K | −$62.7M | — | — |
| FY2021 · to Dec 31 | $4.4M | — | −$96.9M | −$97.1M | -2201.6% | -2.35 | −$78.2M | $12.1M | −$90.4M | — | — |
| FY2020 · to Dec 31 | $8.2M | — | −$54.8M | −$49M | -599.2% | -1.91 | −$34.3M | $204K | −$34.5M | — | — |
Every number comes from Altimmune, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.